Todays Report: The Alps Advisors Inc. Acquires 14,873 Shares of Regulus Therapeutics Inc. (RGLS)

The Alps Advisors Inc. Acquires 14,873 Shares of Regulus Therapeutics Inc. (RGLS)

Alps Advisors Inc. increased its stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 25.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,146 shares of the biopharmaceutical company’s stock after buying an additional 14,873 shares during the period. Alps Advisors Inc.’s holdings in Regulus Therapeutics were worth $214,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in RGLS. Metropolitan Life Insurance Co. NY raised its stake in shares of Regulus Therapeutics by 11.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 24,330 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 2,412 shares in the last quarter. Amici Capital LLC bought a new stake in shares of Regulus Therapeutics during the first quarter valued at approximately $295,000. Geode Capital Management LLC raised its stake in shares of Regulus Therapeutics by 0.7% in the first quarter. Geode Capital Management LLC now owns 183,740 shares of the biopharmaceutical company’s stock valued at $1,273,000 after buying an additional 1,214 shares in the last quarter. State Street Corp raised its stake in shares of Regulus Therapeutics by 9.6% in the first quarter. State Street Corp now owns 377,896 shares of the biopharmaceutical company’s stock valued at $2,618,000 after buying an additional 33,219 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Regulus Therapeutics by 3.8% in the first quarter. Goldman Sachs Group Inc. now owns 774,070 shares of the biopharmaceutical company’s stock valued at $5,364,000 after buying an additional 28,265 shares in the last quarter. 51.47% of the stock is currently owned by institutional investors and hedge funds.

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) traded down 4.22% during trading on Friday, reaching $2.95. 591,578 shares of the company traded hands. Regulus Therapeutics Inc. has a 52 week low of $2.44 and a 52 week high of $10.60. The company’s market capitalization is $155.82 million. The company’s 50-day moving average price is $3.30 and its 200-day moving average price is $4.64.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.02. Regulus Therapeutics had a negative net margin of 456.47% and a negative return on equity of 56.13%. Equities research analysts forecast that Regulus Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

Several analysts have commented on RGLS shares. Chardan Capital lowered their price objective on shares of Regulus Therapeutics from $20.00 to $13.50 and set a “buy” rating on the stock in a research report on Tuesday, June 28th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Thursday, August 4th. Zacks Investment Research raised shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th. BMO Capital Markets lowered shares of Regulus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $16.00 to $4.00 in a research report on Tuesday, June 28th. Finally, Wedbush reissued an “outperform” rating and issued a $15.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 3rd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $10.17.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Related posts

Leave a Comment